Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

4.840 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,936
Open 4.840
Bid (Size) 4.800 (10)
Ask (Size) 4.840 (4)
Prev. Close 4.840
Today's Range 4.840 - 4.840
52wk Range 3.420 - 20.70
Shares Outstanding 36,130,121
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
UROGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against UroGen Pharma Ltd. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd.  - URGN
From Pomerantz LLP
Via GlobeNewswire

Performance

YTD
-54.8%
-54.8%
1 Month
-57.0%
-57.0%
3 Month
-50.3%
-50.3%
6 Month
-61.2%
-61.2%
1 Year
-64.4%
-64.4%

More News

Read More
Deadline Approaching: UroGen Pharma Ltd. (URGN) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
From Law Offices of Howard G. Smith
Via Business Wire
UroGen Presents uTRACT Registry at ASCO 2025 Annual Meeting Designed to Study Real-World Use of JELMYTO in Low-Grade Upper Tract Urothelial Cancer
From UroGen Pharma Ltd.
Via Business Wire
UroGen Announces Data at ASCO 2025 Annual Meeting on UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
From UroGen Pharma Ltd.
Via Business Wire
URGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
URGN ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of UroGen Pharma Ltd. Investors
From Kirby McInerney LLP
Via Business Wire
URGN Investor Notice: Robbins LLP Reminds Stockholders of the Class Action Lawsuit Against UroGen Pharma Ltd.
From Robbins LLP
Via GlobeNewswire
URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
URGN BREAKING NEWS: UroGen Pharma Ltd. Stock Plummets 45% Triggering Shareholder Class Action – Contact BFA Law if You Lost Money (NASDAQ:URGN)
From Bleichmar Fonti & Auld LLP
Via Business Wire
Deadline Alert: UroGen Pharma Ltd. (URGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
From Glancy Prongay & Murray LLP
Via Business Wire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen
From Faruqi & Faruqi, LLP
Via Business Wire
Law Offices of Howard G. Smith Encourages UroGen Pharma Ltd. (URGN) Investors To Inquire About Securities Fraud Class Action
From Law Offices of Howard G. Smith
Via Business Wire
URGN CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against UroGen Pharma Ltd.
From The Law Offices of Frank R. Cruz
Via Business Wire
URGN CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit On Behalf Of UroGen Pharma Ltd. Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN
From Pomerantz LLP
Via GlobeNewswire
UroGen Pharma to Present at TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma Stock Receives Downgrade As Analyst Cites FDA Panel Setback For Key Bladder Cancer Drug
Via Benzinga
Exposures Product Safety
Kaplan Fox Reminds Investors of UroGen Pharma Ltd. (URGN) to an Investigation of Potential Securities Law Violations
Via NewMediaWire
Exposures Product Safety
Kaplan Fox Reminds Investors of UroGen Pharma Ltd. (URGN) to an Investigation of Potential Securities Law Violations
Via TheNewswire.com
Exposures Product Safety
Kaplan Fox is Investigating Potential Securities Law Violations against UroGen Pharma Ltd. (URGN)
Via NewMediaWire
Exposures Product Safety
Kaplan Fox is Investigating Potential Securities Law Violations against UroGen Pharma Ltd. (URGN)
Via TheNewswire.com
Exposures Product Safety
Kaplan Fox Announces an Investigation Into UroGen Pharma Ltd. (URGN) for Potential Securities Law Violations
Via NewMediaWire
Exposures Product Safety
Kaplan Fox Announces an Investigation Into UroGen Pharma Ltd. (URGN) for Potential Securities Law Violations
Via TheNewswire.com
Exposures Product Safety
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd.  - URGN
From Pomerantz LLP
Via GlobeNewswire

Frequently Asked Questions

Is UroGen Pharma Ltd. - Ordinary Shares publicly traded?
Yes, UroGen Pharma Ltd. - Ordinary Shares is publicly traded.
What exchange does UroGen Pharma Ltd. - Ordinary Shares trade on?
UroGen Pharma Ltd. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for UroGen Pharma Ltd. - Ordinary Shares?
The ticker symbol for UroGen Pharma Ltd. - Ordinary Shares is URGN on the Nasdaq Stock Market
What is the current price of UroGen Pharma Ltd. - Ordinary Shares?
The current price of UroGen Pharma Ltd. - Ordinary Shares is 4.840
When was UroGen Pharma Ltd. - Ordinary Shares last traded?
The last trade of UroGen Pharma Ltd. - Ordinary Shares was at 06/02/25 04:00 PM ET
What is the market capitalization of UroGen Pharma Ltd. - Ordinary Shares?
The market capitalization of UroGen Pharma Ltd. - Ordinary Shares is 174.87M
How many shares of UroGen Pharma Ltd. - Ordinary Shares are outstanding?
UroGen Pharma Ltd. - Ordinary Shares has 175M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.